R
Retinal Consultants Medical Group | Modesto, CA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Faricimab
EYE103
Pegcetacoplan
Tarcocimab
Parent organization
This site is a part of Retinal Consultants Medical Group
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 4 total trials
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...
Enrolling
Diabetic Macular Edema (DME)
Neovascular Age-related Macular Degeneration (NVAMD)
Drug: EYE103
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Enrolling
Diabetic Macular Edema
Drug: Faricimab
Trial sponsors
A
E
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems